Literature DB >> 28342636

Rituximab as first-line treatment of pemphigus.

Enno Schmidt1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28342636     DOI： 10.1016/S0140-6736(17)30787-0

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  6 in total

Review 1.  [Immunoadsorption in dermatology].

Authors:  Franziska Hübner; Michael Kasperkiewicz; Detlef Zillikens; Enno Schmidt
Journal:  Hautarzt       Date:  2019-01       Impact factor: 0.751

2.  Tissue Destruction in Bullous Pemphigoid Can Be Complement Independent and May Be Mitigated by C5aR2.

Authors:  Christian M Karsten; Tina Beckmann; Maike M Holtsche; Jenny Tillmann; Sabrina Tofern; Franziska S Schulze; Eva Nina Heppe; Ralf J Ludwig; Detlef Zillikens; Inke R König; Jörg Köhl; Enno Schmidt
Journal:  Front Immunol       Date:  2018-03-15       Impact factor: 7.561

Review 3.  A New Classification System for IgG4 Autoantibodies.

Authors:  Inga Koneczny
Journal:  Front Immunol       Date:  2018-02-12       Impact factor: 7.561

4.  Immunoadsorption of Desmoglein-3-Specific IgG Abolishes the Blister-Inducing Capacity of Pemphigus Vulgaris IgG in Neonatal Mice.

Authors:  Maxi Hofrichter; Jenny Dworschak; Shirin Emtenani; Jana Langenhan; Fanny Weiß; Lars Komorowski; Detlef Zillikens; Winfried Stöcker; Christian Probst; Enno Schmidt; Stephanie Goletz
Journal:  Front Immunol       Date:  2018-09-03       Impact factor: 7.561

5.  Rituximab Therapy for Treatment of Pemphigus in Southeast Asians.

Authors:  Silada Kanokrungsee; Tanaporn Anuntrangsee; Jutamas Tankunakorn; Ploychompoo Srisuwanwattana; Poonkiat Suchonwanit; Kumutnart Chanprapaph
Journal:  Drug Des Devel Ther       Date:  2021-04-22       Impact factor: 4.162

Review 6.  Rituximab as the treatment of pemphigus vulgaris in the COVID-19 pandemic era: A narrative review.

Authors:  Amir Mohammad Beyzaee; Ghasem Rahmatpour Rokni; Anant Patil; Mohamad Goldust
Journal:  Dermatol Ther       Date:  2020-10-20       Impact factor: 3.858
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.